OBJECTIVE: We developed clinical practice guidelines to assess the individual risk-benefit profile of @entity342 replacement therapy in adult @entity14136 (HG), defined by the presence of specific signs and symptoms and serum @entity251 (T) below 12  nmol/L. @entity1 : The task force consisted of eight clinicians experienced in treating HG, selected by the Italian Society of Endocrinology (SIE). The authors received no corporate funding or remuneration. CONSENSUS PROCESS: Consensus was guided by a systematic review of controlled trials conducted on @entity1 with a mean T  <  12  nmol/L and by interactive discussions. The guidelines were reviewed and sequentially approved by the SIE Guidelines Commission and Executive Committee. CONCLUSIONS: We recommend @entity1619 ( @entity1619 ) for adult @entity1 with severely reduced T levels (T  <  8  nmol/L) to improve body composition and sexual function. We suggest that @entity1619 be offered to subjects with T  <  12  nmol/L to improve glycaemic control, lipid profile, sexual function, bone mineral density, muscle mass and @entity308 , once major contraindications have been ruled out. We suggest that lifestyle changes and other available interventions (e.g. for @entity323 ) be suggested prior to @entity1619 . We suggest that @entity1619 should be combined with currently available treatments for individuals at high risk for complications, such as those with @entity170 and/or @entity209 . We recommend against using @entity1619 to improve cardiac outcome and limited mobility. We recommend against using @entity1619 in @entity1 with @entity263 , unstable cardiovascular conditions or elevated haematocrit. The task force places a high value on the timely treatment of younger and middle-aged subjects to prevent the long-term consequences of hypoandrogenism.

Outcomes of XXXX replacement therapy in adult @entity14136 : recommendations from the Italian society of endocrinology.

@entity1 :: ('9606', 'Species') :: ['PARTICIPANTS', 'men'] @entity251 :: ('MESH:D013739', 'Chemical') :: ['testosterone'] @entity1619 :: ('MESH:D015458', 'Disease') :: ['TS', 'T supplementation'] @entity308 :: ('MESH:D003866', 'Disease') :: ['depressive symptoms'] @entity323 :: ('MESH:D007172', 'Disease') :: ['erectile dysfunction'] @entity263 :: ('MESH:D011471', 'Disease') :: ['prostate cancer'] @entity170 :: ('MESH:D010024', 'Disease') :: ['osteoporosis'] @entity342 :: ('CHEBI:50113', 'Chemical') :: ['androgen'] @entity209 :: ('MESH:D008659', 'Disease') :: ['metabolic disorders'] @entity14136 :: ('MESH:D005058', 'Disease') :: ['male hypogonadism']
@entity342 :: (CHEBI:50113,Chemical) :: ['androgen']
